RICHMAP
RICHMAP · Stock · NASDAQ NMS - GLOBAL MARKET ← Markets

DXCM · NASDAQ NMS - GLOBAL MARKET

Dexcom Inc

Health Care
$87.9
▼ 1.81 (2.02%)
Finnhub · 26. 9. 5. 오전 5:00 기준 (실시간~15분 지연)
GLOBAL MARKET WIRE DXCM

Dexcom Inc를 보는 글로벌 시선

이 종목 직접 발언을 우선한 글로벌 증권사·투자대가의 공개 원문 · RICHMAP 추천 아님

LOAD
CALL TRACKER검증 전체 →
차트 TradingView

재무 요약

Finnhub /stock/metric · 연간 기준 · 캐시 6h
PER (연간)
40.47
EPS (연간)
2.06
매출/주 (연간)
11.50
총이익률 (연간)
62.09%
영업이익률 (연간)
19.56%
순이익률 (연간)
데이터 없음
ROE
30.46%
배당수익률
데이터 없음
52주 최고
92.59
52주 최저
54.11
시총 (M)
33,170 USDM
상장 주식수 (M)
385.87

▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)

관련 뉴스

Finnhub /company-news · 최근 14일 · 캐시 30min
Yahoo · 2026. 9. 4.

DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair

DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sit…

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 4.

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 3.

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input…

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 2.

3 Reasons DXCM Has Explosive Upside Potential

Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid qu…

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 1.

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO, September 01, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, Septe…

원문 보기 ↗ Yahoo
Yahoo · 2026. 8. 31.

Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

원문 보기 ↗ Yahoo
Yahoo · 2026. 8. 30.

Everything I Learned from My Hot Chart Summer, and How My 21 Stocks Picks Have Performed.

Great stock picks are just the start to building a portfolio that can shelter you through whatever the market brings.

원문 보기 ↗ Yahoo
Yahoo · 2026. 8. 28.

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close tha…

원문 보기 ↗ Yahoo
ChartMill · 2026. 8. 27.

DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation

Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.

원문 보기 ↗ ChartMill
Yahoo · 2026. 8. 27.

Dexcom, Abbott await Medicare coverage expansion for CGMs

Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.

원문 보기 ↗ Yahoo
Benzinga · 2026. 8. 26.

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

원문 보기 ↗ Benzinga
Yahoo · 2026. 8. 26.

Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.

원문 보기 ↗ Yahoo
⚡ WHAT-IF ARENA · SIMULATION · 가상 · 실제 거래 아님

내 성향 트레이더로 도전

주어는 당신의 성향이지 이 종목이 아닙니다. 6시간부터 1년까지 운용기간을 고르면, AI가 기간에 맞는 주기로 가상 매매합니다. 페이지를 닫아도 서버에서 계속 진행됩니다.

⚠ 정보 제공 목적 · 투자 추천·자문 아님

본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.